Literature DB >> 11254570

Induction of protective immunity against Streptococcus mutans colonization after mucosal immunization with attenuated Salmonella enterica serovar typhimurium expressing an S. mutans adhesin under the control of in vivo-inducible nirB promoter.

Y Huang1, G Hajishengallis, S M Michalek.   

Abstract

The purpose of the present study was to evaluate the effectiveness of an attenuated Salmonella enterica serovar Typhimurium vaccine strain expressing the saliva-binding region (SBR) of the Streptococcus mutans antigen I/II adhesin, either alone or linked with the mucosal adjuvant cholera toxin A2 and B subunits (CTA2/B) and under the control of the anaerobically inducible nirB promoter, in inducing a protective immune response against S. mutans infection. BALB/c mice were immunized by either the intranasal or the intragastric route with a single dose of 10(9) or 10(10) Salmonella CFU, respectively. The Salmonella vaccine strain expressing an unrelated antigen (fragment C of tetanus toxin [TetC]) was also used for immunization as a control. Samples of serum and secretion (saliva and vaginal washes) were collected prior to and following immunization and assessed for antibody activity by enzyme-linked immunosorbent assay. Anti-SBR antibodies were detected in the serum and saliva of experimental animals by week 3 after immunization. A booster immunization at week 17 after the initial immunization resulted in enhanced immune responses to the SBR. The serum immunoglobulin G subclass profiles were indicative of T helper type 1 responses against both the vector and the SBR antigen. To determine the effectiveness of these responses on the protection against S. mutans infection, mice were challenged after the second immunization with a virulent strain of S. mutans which was resistant to tetracycline and erythromycin. Prior to the challenge, mice were treated for 5 days with tetracycline, erythromycin, and penicillin. S. mutans was initially recovered from all of the challenged mice. This bacterium persisted at high levels for at least 5 weeks in control TetC-immunized or nonimmunized mice despite the reappearance of indigenous oral organisms. However, mice immunized with Salmonella clones expressing SBR or SBR-CTA2/B demonstrated a significant reduction in the number of S. mutans present in plaque compared to the control groups. These results provide evidence for the effectiveness of the Salmonella vector in delivering the SBR antigen for the induction of mucosal and systemic immune responses to SBR. Furthermore, the induction of a salivary anti-SBR response corresponded with protection against S. mutans colonization of tooth surfaces.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11254570      PMCID: PMC98142          DOI: 10.1128/IAI.69.4.2154-2161.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

Review 1.  Functional diversity of helper T lymphocytes.

Authors:  A K Abbas; K M Murphy; A Sher
Journal:  Nature       Date:  1996-10-31       Impact factor: 49.962

2.  Construction and oral immunogenicity of a Salmonella typhimurium strain expressing a streptococcal adhesin linked to the A2/B subunits of cholera toxin.

Authors:  G Hajishengallis; E Harokopakis; S K Hollingshead; M W Russell; S M Michalek
Journal:  Vaccine       Date:  1996-11       Impact factor: 3.641

3.  Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits.

Authors:  G Hajishengallis; S K Hollingshead; T Koga; M W Russell
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

4.  Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit.

Authors:  M W Russell; Z Moldoveanu; P L White; G J Sibert; J Mestecky; M Michalek S
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

5.  Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella.

Authors:  J L VanCott; H F Staats; D W Pascual; M Roberts; S N Chatfield; M Yamamoto; M Coste; P B Carter; H Kiyono; J R McGhee
Journal:  J Immunol       Date:  1996-02-15       Impact factor: 5.422

6.  Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits.

Authors:  E Harokopakis; G Hajishengallis; T E Greenway; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

7.  Role of the Streptococcus mutans gtf genes in caries induction in the specific-pathogen-free rat model.

Authors:  Y Yamashita; W H Bowen; R A Burne; H K Kuramitsu
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Oral immunization with recombinant Salmonella typhimurium expressing surface protein antigen A of Streptococcus sobrinus: dose response and induction of protective humoral responses in rats.

Authors:  T K Redman; C C Harmon; R L Lallone; S M Michalek
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

9.  Cholera toxin and Salmonella typhimurium induce different cytokine profiles in the gastrointestinal tract.

Authors:  G R Klimpel; M Asuncion; J Haithcoat; D W Niesel
Journal:  Infect Immun       Date:  1995-03       Impact factor: 3.441

10.  Affinity and specificity of the interactions between Streptococcus mutans antigen I/II and salivary components.

Authors:  G Hajishengallis; T Koga; M W Russell
Journal:  J Dent Res       Date:  1994-09       Impact factor: 6.116

View more
  20 in total

Review 1.  Microbial/host interactions: mechanisms involved in host responses to microbial antigens.

Authors:  Suzanne M Michalek; Jannet Katz; Noel K Childers; Michael Martin; Daniel F Balkovetz
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  A therapeutic anti-Streptococcus mutans monoclonal antibody used in human passive protection trials influences the adaptive immune response.

Authors:  Rebekah A Robinette; Monika W Oli; William P McArthur; L Jeannine Brady
Journal:  Vaccine       Date:  2011-06-23       Impact factor: 3.641

3.  Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses.

Authors:  Oscar Pino; Michael Martin; Suzanne M Michalek
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Effect of attenuated Salmonella enterica serovar Typhimurium expressing a Streptococcus mutans antigen on secondary responses to the cloned protein.

Authors:  C Jespersgaard; P Zhang; G Hajishengallis; M W Russell; S M Michalek
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

5.  Enhanced immunogenicity of a genetic chimeric protein consisting of two virulence antigens of Streptococcus mutans and protection against infection.

Authors:  Ping Zhang; Christina Jespersgaard; Leticia Lamberty-Mallory; Jannet Katz; Yan Huang; George Hajishengallis; Suzanne M Michalek
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Alterations in immunodominance of Streptococcus mutans AgI/II: lessons learned from immunomodulatory antibodies.

Authors:  Rebekah A Robinette; Kyle P Heim; Monika W Oli; Paula J Crowley; William P McArthur; L Jeannine Brady
Journal:  Vaccine       Date:  2013-11-16       Impact factor: 3.641

7.  Role of Toll-like receptors in host responses to a virulence antigen of Streptococcus mutans expressed by a recombinant, attenuated Salmonella vector vaccine.

Authors:  Mohammad Abdus Salam; Jannet Katz; Suzanne M Michalek
Journal:  Vaccine       Date:  2010-07-12       Impact factor: 3.641

8.  Safety and immunogenicity of Salmonella typhimurium expressing C-terminal truncated human IL-2 in a murine model.

Authors:  Brent Sorenson; Kaysie Banton; Lance Augustin; Sean Barnett; Karen McCulloch; Joshua Dorn; Natalie Frykman; Arnold Leonard; Daniel Saltzman
Journal:  Biologics       Date:  2010-03-24

9.  Impact of vector priming on the immunogenicity of recombinant Salmonella vaccines.

Authors:  Christofer J Vindurampulle; Stephen R Attridge
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

10.  Oral vaccination with a recombinant Salmonella vaccine vector provokes systemic HIV-1 subtype C Gag-specific CD4+ Th1 and Th2 cell immune responses in mice.

Authors:  Nyasha Chin'ombe; William R Bourn; Anna-Lise Williamson; Enid G Shephard
Journal:  Virol J       Date:  2009-06-25       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.